Cosmos Health earnings release, May 22, 2026

Cosmos Health Inc. (COSM) · Form 8-K, Item 2.02 · Filed · SEC filing

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

CHICAGO, IL /

ACCESS Newswire

/ May 21, 2026 /

Cosmos Health Inc.

(“Cosmos Health” or the “Company”)

(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

Income Statement

Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength — over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.

Balance Sheet

Cosmos Health continued to improve its balance sheet in Q1 2026, with active debt reduction and working capital optimization driving an improvement in the liabilities-to-assets ratio to 68.2% from 71.9% at year-end 2025.

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated:

“Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division — record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories.

This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization — in personnel, facilities, infrastructure, technology, and AI-driven efficiencies — to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nutraceuticals market through the 18 Series platform. Adjusted EBITDA is near breakeven, and we expect it to turn positive as our growth investments drive meaningful returns and revenues continue to scale.

At the same time, we have been disciplined in managing our balance sheet. We reduced total liabilities by $4.5 million in a single quarter, a 9.6% reduction, driven by a substantial reduction in convertible note and credit facility balances. Meanwhile, stockholders' equity increased by 7.6%, our liabilities-to-assets ratio improved by 370 basis points, and our liquidity position remains solid, with $4.3 million in liquid assets including cash of $2.2 million, to support our growth plans.

Q1 2026 is an early indication of what we believe will be a period of significant growth for Cosmos Health, and we look forward to updating our shareholders as this story continues to unfold.”

Financial statements

Income Statement

Three Months Ended March 31, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
GAAP FiguresREVENUE17,927,89213,712,528
GAAP FiguresGROSS PROFIT1,381,1712,049,799
GAAP FiguresTOTAL OPERATING EXPENSES-3,565,350-2,882,944
GAAP FiguresGAIN (LOSS) FROM OPERATIONS-2,184,179-833,145
GAAP FiguresTOTAL OTHER INCOME (EXPENSE), NET-621,24415,048
GAAP FiguresNET GAIN (LOSS)-2,805,423-818,097
NON-GAAP Figures*ADJUSTED REVENUE18,398,49313,712,528
NON-GAAP Figures*ADJUSTED GROSS PROFIT1,851,7722,049,799
NON-GAAP Figures*ADJUSTED EBITDA-229,596373,119
NON-GAAP Figures*ADJUSTED NET INCOME (LOSS)-996,502277,338

Income Statement

Three Months Ended March 31,

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
(in $)REVENUE17,927,89213,712,528
(in $)Sales discount reversal470,601
(in $)ADJUSTED REVENUE18,398,49313,712,528
(in $)GROSS PROFIT1,381,1712,049,799
(in $)Sales discount reversal470,601
(in $)ADJUSTED GROSS PROFIT1,851,7722,049,799
(in $)INCOME (LOSS) BEFORE INCOME TAXES-2,805,423-818,097
Adjustments (add back):Depreciation and amortization expense348,179320,439
Adjustments (add back):Interest (income) / expense, net766,90695,781
Adjustments (add back):EBITDA-1,690,338-401,877
Adjustments (add back):Sales discount reversal470,601
Adjustments (add back):Non-recurring and extraordinary items245,116135,621
Adjustments (add back):Stock-based compensation535,786556,611
Adjustments (add back):Other income (expense), net-86,161261,730
Adjustments (add back):Change in fair value of derivative liability & convertible notes-471,448
Adjustments (add back):(Gain) / loss on equity investments & digital assets, net453,691-3,142
Adjustments (add back):Foreign currency transaction, net313,157-175,824
Adjustments (add back):ADJUSTED EBITDA-229,596373,119
Adjustments (add back):Interest income / (expense), net-766,906-95,781
Adjustments (add back):ADJUSTED NET INCOME (LOSS)-996,502277,338

Balance Sheet

March 31, 2026 — CONDENSED CONSOLIDATED BALANCE SHEET DATA

March 31, 2026 – (Unaudited)December 31, 2025 – (Audited)September 30, 2025 – (Unaudited)
ASSETSCash & cash equivalents2,158,9213,459,8934,633,660
ASSETSInventory5,650,4585,778,1425,683,662
ASSETSAccounts receivable, prepaid expenses and other current assets28,594,75228,662,58325,952,190
ASSETSProperty and equipment, net10,280,20310,578,85810,664,820
ASSETSGoodwill and intangible assets, net7,225,0117,569,6957,960,633
ASSETSLoans receivable3,605,3883,633,8397,666,483
ASSETSOther noncurrent assets4,854,2785,794,5086,931,310
ASSETSTOTAL ASSETS62,369,01165,477,51869,492,758
LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable and accrued expenses15,689,06117,412,97315,198,777
LIABILITIES AND STOCKHOLDERS' EQUITYOther current liabilities6,701,0516,047,9405,505,549
LIABILITIES AND STOCKHOLDERS' EQUITYLines of credit7,856,2089,177,6847,584,786
LIABILITIES AND STOCKHOLDERS' EQUITYNotes payable9,954,81211,485,08415,956,667
LIABILITIES AND STOCKHOLDERS' EQUITYOther non-current and finance/lease liabilities2,341,5202,929,2082,112,095
LIABILITIES AND STOCKHOLDERS' EQUITYStockholders' and mezzanine equity19,826,35918,424,62923,134,885
LIABILITIES AND STOCKHOLDERS' EQUITYTOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY62,369,01165,477,51869,492,758

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Cosmos Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.